Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	4DS Memory Limited
ABN	43 145 590 110

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr David McAuliffe
Date of last notice	21 January 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Concept Biotech Pty Ltd (director related entity) David Jerimiah McAuliffe <the d9m="" investment="" lazy="" trust=""> (trustee and beneficiary) Margaret Elizabeth Livingston (spouse)</the>	
Date of change	6 May 2019	
No. of securities held prior to change	Direct David McAuliffe 2,521,839 fully paid ordinary shares Indirect Concept Biotech Pty Ltd 2,498,812 fully paid ordinary shares David Jerimiah McAuliffe <d9m investment="" trust=""> 8,056,743 fully paid ordinary shares</d9m>	
Class	Unlisted options	
Number acquired	Indirect – 7,000,000 exercisable at \$0.052 each on or before 22 January 2024	
Number disposed	-	
Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	Nil	

⁺ See chapter 19 for defined terms.

No. of securities held after	Direct	
change	David McAuliffe	
	2,521,839 fully paid ordinary shares	
	Indirect	
	Concept Biotech Pty Ltd	
	2,498,812 fully paid ordinary shares	
	<u>David Jerimiah McAuliffe<d9m investment="" trust=""></d9m></u>	
	8,056,743 fully paid ordinary shares	
	Margaret Elizabeth Livingston	
	7,000,000 unlisted options exercisable at \$0.052 each on or before	
	22 January 2024, with 1,250,000 subject to vesting conditions	
Nature of change	Issue of options as approved by shareholders on 24 April 2019	
Example: on-market trade, off-market trade, exercise of options, issue of securities under	· · · · · · · · · · · · · · · ·	
dividend reinvestment plan, participation in		
buy-back		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

sciosed iii tilis part.	
Detail of contract	N/A-
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

are crossa perioa	
Were the interests in the securities or contracts detailed above	No
traded during a +closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.